Cell News and Research

RSS

More than 22,000 Americans expected to be diagnosed with a malignant brain tumor in 2009

It is expected that more than 22,000 Americans will be diagnosed with a malignant brain tumor in 2009. Senator Ted Kennedy's death from a brain cancer draws attention to a rare, but often fatal type disease. While the risk of developing brain cancer is relatively low, it is important to heed the warning signs and receive an accurate diagnosis.

27 Aug 2009

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

Despite recent advances in diagnosis and treatment, the prognosis of patients with biliary tract cancer is still poor. Elucidating the biological characteristics of these carcinomas has become necessary to improve the prognosis of patients and to devise better treatment strategies. A recent study report that invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in the progression of biliary tract cancer.

26 Aug 2009

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.

26 Aug 2009

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

26 Aug 2009

Cannabis chemicals halt prostate cancer growth

Active chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer.

26 Aug 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Herbalscience research throws light on causes of allergic rhinitis

Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation. But nettle has also been used for hundreds of years to treat seasonal allergies and other inflammatory diseases, although the precise nature of its anti-inflammatory effect was unknown. Now, scientists with HerbalScience have identified specific bioactives in nettle leaf extracts that inhibit in vitro receptors and enzymes known to be key in generating symptoms of allergic rhinitis, or hay fever.

26 Aug 2009

Oxygen Biotherapeutics to present at the Rodman & Renshaw Annual Global Investment Conference

Oxygen Biotherapeutics, Inc. today announced that the company will present at investor conferences in New York on Sept. 9 and Zurich on Sept. 10, 2009.

26 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Cardium Therapeutics (NYSE Amex: CXM) today announced that all patients enrolled in the Company's MATRIX clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Defentect's radiation detection system to be installed at Washington Hospital Center

Defentect announced today Washington Hospital Center is deploying Defentect's radiation detection system hospital-wide following a pilot project to test its effectiveness, with an additional nine GT2(TM) radiation sensors and two GT4(TM) Gamma Radiation sensors, capable of isotopic identification.

26 Aug 2009

Mid-career scientists receive the 2009 Julie Martin Mid-Career Awards in Aging Research

Charleen T. Chu, MD, PhD, associate professor at the University of Pittsburgh and David M. Sabatini, MD, PhD, associate professor, Massachusetts Institute of Technology, received the 2009 Julie Martin Mid-Career Awards in Aging Research. Sponsored by The Ellison Medical Foundation, the grants provide funding of $550,000 to mid-career scientists whose research has great potential in advancing understanding of basic aging and its impact on age-related diseases.

26 Aug 2009

New drug delivery system for delivering nanoparticles into the tissue

Scientists at UC Santa Barbara have discovered a potential new drug delivery system. The finding is a biological mechanism for delivery of nanoparticles into tissue. The results are published in this week's Proceedings of the National Academy of Sciences.

26 Aug 2009

Kinase inhibitors can arrest growth of cancer cells at early stages

Scientists have discovered a way of allowing healthy cells to take charge of cancerous cells and stop them developing into tumours in what could provide a new approach to treating early-stage cancers.

From The University of Manchester 26 Aug 2009

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.

26 Aug 2009

MicroRNAs in saliva could aid in the detection of oral cancer

Researchers continue to add to the diagnostic alphabet of saliva by identifying the presence of at least 50 microRNAs that could aid in the detection of oral cancer, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

26 Aug 2009

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

A new study published by researchers at the UCLA School of Dentistry substantiates the effectiveness of measuring the microRNAs present in saliva to detect oral squamous cell carcinoma. Like hall monitors in an elementary school, microRNAs are the molecules produced by cells that simultaneously asses the behavior of multiple genes and control their activity.

25 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

25 Aug 2009

Cell News and Research

More than 22,000 Americans expected to be diagnosed with a malignant brain tumor in 2009

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

Cannabis chemicals halt prostate cancer growth

Important development in the treatment of multiple sclerosis

Herbalscience research throws light on causes of allergic rhinitis

Oxygen Biotherapeutics to present at the Rodman & Renshaw Annual Global Investment Conference

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Defentect's radiation detection system to be installed at Washington Hospital Center

Mid-career scientists receive the 2009 Julie Martin Mid-Career Awards in Aging Research

New drug delivery system for delivering nanoparticles into the tissue

Kinase inhibitors can arrest growth of cancer cells at early stages

Gloucester Pharmaceuticals raises funds for the development of romidepsin

MicroRNAs in saliva could aid in the detection of oral cancer

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News